Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several dosing and administration points (once daily; with or without food) align with the label excerpts, but multiple claims about dairy/food effects and atypical safety/interaction framing are not supported by the provided FDA labeling. Several safety-related prompts (muscle pain/weakness, dark urine, fatigue) are partially aligned with labeled risks of myopathy/rhabdomyolysis but the specific triggers and causality are not supported in the provided excerpts.
Category Scores
Accurate Statements
Lipitor is often taken once daily.
Label Section 2.1: recommended starting dose 10 or 20 mg once daily; dosage range 10 to 80 mg once daily.
Lipitor can be taken with food or on an empty stomach.
Label Section 2.1: “can be administered as a single dose at any time of the day, with or without food.”
New muscle pain or weakness after starting Lipitor should prompt contact with a clinician.
Label Section 17.1: patients starting therapy should report promptly any unexplained muscle pain; label also notes risk of myopathy and that therapy should be withheld/discontinued in acute serious suggestive of myopathy (Section 5.1).
Unsupported Statements
Lipitor (atorvastatin) does not have a general restriction against taking it with dairy foods like milk or yogurt.
Provided label excerpts do not mention dairy-specific restrictions; absence of a statement is not evidence of “no restriction.” The only food-related statement provided is that food decreases the rate/extent of absorption but LDL-C reduction is similar with or without food (Section 12.3).
You can usually take Lipitor with a meal that includes milk or yogurt without needing to avoid those foods.
No dairy-specific counseling is provided in the excerpts. The label excerpt supports “with or without food” generally (Section 2.1; Section 12.3) but does not address milk/yogurt specifically.
Dairy does not meaningfully change atorvastatin absorption or safety for most people.
No dairy-specific pharmacokinetic or safety data are included in the provided labeling excerpts.
The bigger dietary interaction people are typically warned about with statins is grapefruit, not milk or yogurt.
Label excerpts include grapefruit juice/CYP3A4 interaction warnings (Sections 7.2 and 17.1) but do not mention milk/yogurt or provide a comparative “bigger” dietary interaction statement.
Eating yogurt with milk is still dairy intake.
This is a general definitional statement and is not supported/assessed by the label excerpts (not a drug labeling claim).
There is no specific known issue that makes taking Lipitor with yogurt different from taking it with other regular foods.
The provided labeling excerpts do not address yogurt specifically.
If milk or yogurt upsets the stomach or helps remember the dose, taking Lipitor with the meal is commonly practical.
The label excerpt supports administration with or without food (Sections 2.1, 12.3) but does not provide patient-practical guidance about milk/yogurt, stomach upset, or recall.
Dark urine after starting Lipitor should prompt contact with a clinician.
The excerpts provided include myopathy/rhabdomyolysis risk counseling (Sections 5.1, 17.1) but do not mention “dark urine” specifically as a prompt-to-contact symptom.
Unusual fatigue after starting Lipitor should prompt contact with a clinician.
No fatigue-specific counseling is present in the provided excerpts. The excerpts list certain adverse reactions (Section 6) and myopathy counseling (Section 17.1) but do not include fatigue as a reported prompt symptom.
Dairy itself is not the usual cause of statin side effects.
No dairy-specific causality statements are present in the provided label excerpts.
Contradictions
Important Omissions
Grapefruit juice quantity threshold and counseling about risk of myopathy increased with larger quantities of grapefruit juice (>1 liter).
Importance:
Moderate
General requirement to report unexplained muscle pain promptly (present in label) is partially covered, but other label safety instructions are not included (e.g., liver function test timing/prior to and after initiation).
Importance:
Moderate
Contraindications: pregnancy (fetal harm; discontinue immediately if pregnant) and breastfeeding, and active liver disease/hypersensitivity—none of which are addressed by the AI statements.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The AI includes some supported dosing and general myopathy reporting guidance, but it introduces multiple unsupported dairy-specific interaction reassurances and symptom-trigger instructions (dark urine, fatigue) that are not corroborated by the provided label excerpts. It also omits several major contraindication/safety counseling elements included in the label (pregnancy, breastfeeding, active liver disease, hypersensitivity).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple dairy-specific statements are not supported by the provided FDA label excerpts; some symptom-specific safety prompts and comparative dietary interaction framing are unsupported.
Suggested Improvement
Remove dairy-specific interaction claims unless the label excerpts explicitly address dairy; keep only label-supported points (administration with or without food; grapefruit juice interaction and >1 liter counseling; report unexplained muscle pain; include key contraindications such as pregnancy/breastfeeding and active liver disease).